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SUMMARY
Malaria is a disease that still aﬀects a signiﬁcant proportion of the global human population.Whilst advances have beenmade
in lowering the numbers of cases and deaths, it is clear that a strategy based solely on disease control year on year, without
reducing transmission and ultimately eradicating the parasite, is unsustainable. This article highlights the current mainstay
treatments alongside a selection of emerging new clinical molecules from the portfolio of Medicines for Malaria Venture
(MMV) and our partners. In each case, the key highlights from each research phase are described to demonstrate how these
new potential medicines were discovered. Given the increased focus of the community on eradicating the disease, the
strategy for next generation combination medicines that will provide such potential is explained.
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INTRODUCTION
Malaria is a parasitic infection of the genus
Plasmodium and has historically been one of the
deadliest diseases for humankind. In recent years,
there has been a reduction in the numbers of deaths
from malaria, and this has been attributed to the
use of insecticide-treated bed-nets, indoor residual
spraying to kill mosquitoes (the vector that carries the
parasite and infects humans) and the availability of
eﬀective, well tolerated and high quality medicines
(Roll Back Malaria, 2012). Indeed according to the
WHO there were 655000 deaths in 2010 which is a
substantial reduction when compared with over a
million at the turn of the millennium (WHO, 2011).
However, since a strategy focused on case manage-
ment risks is unsustainable in the long term there has
been an increased focus to target the elimination
and eradication of the parasite (Alonso et al. 2011).
This challenging goal will require the combined
and sustained application of the entire community
including: (1) renewed eﬀorts to develop insecticides
that overcome known resistance pathways and kill
all mosquitoes; (2) the delivery of eﬀective vaccines
that protect infants and children; (3) the delivery of
appropriate and sensitive diagnostics to guide health
care tactics, and (4) the discovery, development and
delivery of new medicines that not only clear the
asexual blood stage parasites and cure patients, but
also kill the asymptomatic and vector-stage forms
that allow transmission ofPlasmodium (Burrows et al.
2011a.)
It is clear that the ﬁght against malaria will involve
chemotherapy as a vital component (White et al.
2011). However, resistance to the existing medicines
is always a risk. Consequently, all treatments must be
combinations of two or more active ingredients such
that no compound is exposed as a monotherapy to
high levels of parasites for a signiﬁcant period of time
wherever possible (Duparc et al. 2012).
CURRENT FIRST LINE THERAPIES
Treatment of clinical symptoms of malaria
The vast majority of cases of malaria are uncompli-
cated disease, where the patient has fever and up to
200000 parasites per microlitre. Artemisinin combi-
nation therapies (ACTs), the ﬁrst line medicines in
this case, are extremely safe and eﬀective after three
days of dosing. These are medicines that combine
an artemisinin derivative (for example artemether,
artesunate or dihydroartemisinin) with a partner
drug. Artemisinin is a natural product and is ex-
tracted from the leaves of the Artemisia annua plant.
Artemisinin derivatives are semi-synthetic peroxides
and are active against all species of Plasmodium;
they are able to clear blood-stage parasites and
reduce fever rapidly (WHO, 2010). Combining an
artemisinin derivative with a partner drug in one
tablet (a ﬁxed-dose combination) is preferred, as
it ensures that both active ingredients are taken,
maximizing eﬃcacy and reducing the potential for
resistance developing.
The partner drugs that are used in these combi-
nations also share their origins in nature, being
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synthetic variants on the natural product quinine.
Broadly speaking they separate into two chemical
classes: the amino-alcohols, which share the closest
similarity to quinine, and the 4-aminoquinolines,
which were early synthetic mimics. The amino-
alcohol class is best illustrated by meﬂoquine
and the more structurally divergent lumefantrine.
Chloroquine, the original exemplar of the
4-aminoquinoline class is no longer in use for
falciparum malaria due to reduced parasite sensi-
tivity. It is now replaced by more recent analogues
without cross resistance: amodiaquine, piperaquine
and the ‘quinacrine-amodiaquine’ hybrid, pyro-
naridine. Structures of these molecules and other
clinical derivatives of each class are shown in Fig. 1
(Burrows et al. 2011).
Treatment of liver-stage vivax malaria
In all cases of infection, the parasite passes from the
mosquito to the liver, usually via the regional lymph
nodes. For Plasmodium falciparum, the dividing or
liver schizont stage lasts for around 6 days. However,
forP. vivax (the key species in Asia and the Americas)
and P. ovale there is also a sub-population of the
liver-stage parasites, called hypnozoites, that appears
to halt its development and become dormant, only to
relapse after a period which can vary between four
weeks and several years. Once the primary blood-
stage infection has been treated, the patient is
asymptomatic and often unaware of the risk associ-
ated with retention of these parasites. Although the
biological mechanisms underlying the activation
Fig. 1. Structures of clinical antimalarials for asexual blood stages.
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process are not understood, it is clear that hypno-
zoites can ‘wake up’ and reactivate leading to a new
blood-stage infection in the absence of a mosquito
bite – a relapse (Price et al. 2007). There is one drug
only that is approved for relapse prevention and that
is the 8-aminoquinoline, primaquine. Primaquine,
however, is a 14-day treatment that is given to
patients who are eﬀectively asymptomatic, but it
has known gastro-intestinal side eﬀects and, more
importantly, presents a risk of haemolytic anaemia
to patients who have low activity of the glucose
6-phosphate dehydrogenase and hence termed ‘G6PD
deﬁcient’ (Baird and Rieckmann, 2003). Con-
sequently, new molecules with improved oral dosing
regimens and no-G6PD deﬁciency liability are a
priority (Wells et al. 2010). The communities’ im-
mediate hope in this regard is the 8-aminoquinoline,
tafenoquine, which beneﬁts from being a single dose.
Tafenoquine is undergoing Phase II/III studies with
GSK and MMV with the aim of establishing the
minimum eﬃcacious and safe dose. The structures of
primaquine and tafenoquine are shown in Fig. 2.
Transmission blocking
Another way to eliminate the disease is to break the
transmission cycle by preventing patients infecting
mosquitoes (Sinden, 2009). The transmission-
blocking potential of many of the existing mainstay
treatments is still poorly understood (Delves et al.
2012). This is partly due to the complexity of clearly
measuring an impact on clinical transmission (i.e.
from human to human) but also because the
biological area, spanning parasite stages in the host
and mosquito, is extremely intricate and the necess-
ary tools are only now starting to emerge (Sinden
et al. 2012a, b). It is clear, however, that a single
dose of primaquine of 0·75mg/kg is eﬀective as a
gametocytocidal agent. As such, it clears mature stage
gametocytes (often called stage V), the infectious
parasite form to the mosquito, from the blood
of patients. Indeed, WHO recommend this in
combination with ACTs as a way of killing all the
gametocytes in patients, preventing the development
of mosquito-stage parasites and thus, by inference,
blocking transmission. However, this dose level has
restrictions: the risk of haemolysis due to G6PD
deﬁciency should be taken into account and the drug
should not be given to pregnant women or infants
under 1 year of age. In 2012, after a review of all data,
WHO extended their recommendation further to
include lower single dose primaquine of 0·25 mg/kg
for all conﬁrmed malaria patients in elimination
regions where the higher single dose primaquine
is not already in use. This low dose is still not
recommended for pregnant women or infants but is
deemed ‘unlikely to cause serious toxicity in subjects
with any of the G6PD variants’ (WHO, 2012a, b).
Chemoprotection
Preventing malaria in vulnerable populations, par-
ticularly expectant mothers and young children, is
still a priority, especially given that the development
of fully protective vaccines is a very challenging task
for protozoal infections. Given the vulnerability of
this patient sector, and the fact that they do not have
malaria at the time of dosing, it is imperative that
such medicines are extremely safe and well tolerated.
Consequently, the combinations being proﬁled or in
use today comprise historical antimalarials which
have an extremely well understood safety proﬁle and,
despite ﬁeld resistance, are combined in a way to
deliver beneﬁt. A combination of azithromycin and
chloroquine (AZCQ) is being developed for pre-
sumptive treatment and future chemoprotection in
pregnancy (Chico et al. 2008). The combination
shows synergy, in that it is active in populations
infected with chloroquine-resistant strains. For
infants, recent ﬁeld data show the success of a triple
combination of sulphadoxine–pyrimethamine–
amodiaquine (SPAQ) in protecting children in the
Sahel region of sub-Saharan Africa, where the season
is only four months long (WHO, 2012a, b). Because
these medicines are historical they are relatively
inexpensive and the cost to protect a child for a year
will be between US$0·40–0·60, making it extremely
cost eﬀective. Structures of these chemoprotectants
are shown in Fig. 3.
RESEARCH PRIORITIES FOR DEVELOPING NEW
DRUGS FOR ERADICATION
Over the past decade, ACTs have played a pivotal role
in malaria control programmes. These drugs will
continue to play an important role in the journey
towards eradication as they will remain the corner-
stone of case management. ACTs are extremely well
tolerated and eﬃcacious, but there are areas for
improvement in the next generation of medicines.
Artemisinin and partner drug resistance is under
close scrutiny; ideally, in combination, two drugs
would have similar pharmacologically eﬀective
Fig. 2. Structures of clinical antimalarials for vivax
radical cure.
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durations in patients, so as to protect each other
comprehensively – this is not achieved in an ACT;
ﬁnally, for eradication, a combination that is ex-
tremely well tolerated across a population and that
clears all parasites in an individual is desirable. Thus,
there is a critical need for a new generation of
medicines to target the challenges of the eradication
agenda (The malERAConsultative Group onDrugs,
2011). Two main types of medicines are envisioned,
one to treat and the other to protect, and Target
Product Proﬁles (TPPs) have been developed that
outline the requirements for these new medicines.
(1) TPP1 –A combination of blood-stage cure, with
transmission blocking, hypnozoiticidal and post-
treatment prophylactic action, which matches or
improves on the simplicity of the ACT 3 day regimen
and (2) TPP2 –A single-exposure chemoprotection,
which matches or improves on the current weekly
chemoprotection given by meﬂoquine, but without
the adverse gastrointestinal or CNS events.
With safe and eﬃcacious products already on
the market, delivery of a multiple-dose blood-stage
treatment will only be relevant if mainstay therapies
fail due to resistance. Patients have been character-
ized in the Thai - Cambodian border region who
show a signiﬁcantly slower response to artesunate in
terms of parasite clearance and, unless this can be
contained, there will be parts of the world in the near
future where ACTs are ineﬀective (Noedl et al. 2008;
Phyo et al. 2012). Another potential diﬀerentiation
for a new medicine would be the potential to be
administered as a single oral dose, which could be
observed directly. This would eliminate the possi-
bility that an incomplete course of therapy is given,
and incomplete therapeutic courses of anti-infectives
are one of the prime causes for the spread of resistant
strains.
An ideal combination requires a variety of
activities: blood-stage cure, transmission blocking,
anti-relapse and post-treatment prophylactic action;
this is the Single Exposure Radical Cure and
Prophylaxis combination (SERCaP) as highlighted
from the output of the malERA consortium and
is the ﬁrst Target Product Proﬁle –TPP1. Such a
medicine would transform drug treatment for
malaria.
A second type of medicine needed in the early
stages of elimination is that of chemoprotection,
and is described by TPP2. Again, ideally this
Single Exposure Chemoprotectant (SEC) would
be able to be given on a once per month basis with
the knowledge that between dosing periods indi-
viduals were protected from primary blood-stage
infections.
As discussed earlier, any new medicines developed
should be a combination of at least two complemen-
tary molecules. Following consultations with its
partners, MMV has deﬁned four Target Candidate
Proﬁles (TCPs), which aim to guide the identiﬁcation
of compounds that might be combined to
produce a medicine that meets the TPPs described
above (Burrows et al. 2013). The four TCPs are:
(1) TCP1 –Rapid parasite clearance molecules that
could replace artemisinin; (2) TCP2 –Molecules
with long half-lives to give post-treatment prophy-
laxis, and replace the current generation of amino-
quinolines or aminoalcohols; (3) TCP3 –Molecules
that kill non-dividing parasite forms such as hypno-
zoites to stop P. vivax relapse (termed 3a) and
gametocytes to stop transmission (termed 3b); and
(4) TCP4 – Slow-onset chemoprophylactics or causal
prophylactics with long duration and excellent safety
proﬁles to protect vulnerable populations in once
endemic regions.
Fig. 3. Structures of clinical combination chemoprotectants.
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GLOBAL MALARIA PORTFOLIO
Over the last decade there has been an increased
investment in antimalarial research and development
and through the work of organizations such as
Medicines for Malaria Venture (MMV), their
partners and others, new molecules with novel
modes of action are entering into pre-clinical devel-
opment and beyond (Anthony et al. 2012). The
current Global Malaria Portfolio can be found at
the following link: http://www.mmv.org/research-
development/rd-portfolio and this is updated on a
quarterly basis.
Despite the relative abundance of projects at
certain stages, taking account of attrition between
each phase and the need for combination medicines,
it is clear that a sustained delivery of high quality
antimalarial preclinical candidates is necessary for at
least a decade.
MMV PORTFOLIO
Within the MMV portfolio, two new compounds
have recently completed Phase IIa studies and there
are an additional six compounds in Phase I or
Preclinical Development. A selection of these is
described below.
OZ439
The most advanced of the new molecules is a
second generation endoperoxide, OZ439, that has
been designed to have superior pharmacokinetics to
the artemisinins. OZ439 has demonstrated clinical
eﬃcacy as a single agent (in phase IIa studies, the
so-called proof of concept). It is now being tested in
combination safety studies, and will start combi-
nation eﬃcacy studies in 2014. Studies in both
healthy volunteers and infected patients show a
signiﬁcant plasma exposure for as long as 20 days,
suggesting it might be possible to use as part of a
single-dose therapy for uncomplicated malaria
(Möhrle et al. 2012). In patients, OZ439 drives the
reduction of parasites at about the same rate as
artesunate. The next step is to identify a suitable
combination partner that will give long-term protec-
tion and support a single-dose cure.
OZ439 comes from the ozonide class of anti-
malarials and was delivered by a project team led by
Jonathan Vennerstrom at Nebraska University, in
collaboration with the Swiss Tropical and Public
Health Institute (Swiss TPH), Monash University
and MMV (Charman et al. 2011). Vennerstrom and
co-workers hypothesized that the endoperoxide in an
ozonide could deliver eﬃcacy equal to that observed
with the natural product artemisinins. The team
demonstrated that a stabilized ozonide, OZ03, with a
simple structure was suﬃcient to give excellent
in vitro potency. The high lipophilicity and low
solubility, however, had to be addressed and this led
to an introduction of polarity and ionizable groups in
a region of the molecule that was synthetically
tractable yet which did not compromise potency.
This initially led to OZ277 (arterolane) which was
the ﬁrst clinical candidate and which was licensed
to Ranbaxy (Vennerstrom et al. 2004). Indeed the
combination of OZ277 and piperaquine received
approval in India in 2012 under the name Synriam™,
and has been widely used to treat malaria patients in
India in the last six months. OZ277, however, has
lower exposure in patients than expected and this was
hypothesized as being due to instability in infected
blood, due to an interaction with ferrous iron.
Vennerstrom’s team, therefore, focused on replacing
the amide with a phenyl ring, that helped to stabilize
the ozonide, and they substituted the amide for an
ether-linked base. The resultant compound, OZ439,
was shown to have improved infected blood stability,
was able to cure mice infected with P. berghei from a
single 30mg/kg dose and was progressed as the
potential single dose cure candidate (see Fig. 4).
NITD609
A second compound in Phase II is a novel, synthetic
spiroindolone, developed by the Novartis Institute
for Tropical Diseases (NITD) in Singapore in
a collaboration that included the Swiss TPH,
the Dutch Biomedical Primate Research Center,
the Genomics Institute of the Novartis Research
Foundation (GNF) and MMV. It was the ﬁrst
Fig. 4. OZ439: Hit to Candidate.
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compound to be developed using whole-cell screen-
ing against the parasite (Rottmann et al. 2010), and
started human proof of concept in 2012, just under
5 years after the initial screen began. It has now
passed proof of concept, and has been shown to clear
parasites in patients infected with either P. vivax or
P. falciparum. The compound inhibits the P-type
sodium transporter ATPase 4 (PfATP4), and this
results in an increase in the concentration of sodium
ions in the parasite, which is toxic to the cell.
The spiroindolone class was found from screening
a library of natural product and ‘natural product like’
compounds at Novartis. The starting ‘hit’, com-
pound 1, had an intriguing structure, good potency
and, impressively for a starting point, suppressed
parasitaemia in the P. bergheimouse model of malaria
by >99% with a single dose of 100mg/kg. Excellent
medicinal chemistry was applied to contract the
seven-membered ring, to deﬁne the stereochemical
structure/activity relationship and to replace the
lipophilic bromine atom. This resulted in compound
2 which had an increased potency yet reduced
lipophilicity – the ideal outcome from medicinal
chemistry. However, its metabolic stability was still
non-optimal; this was ﬁxed by judicious positioning
of halogens on the tetrahydro-beta-carboline ring.
The resulting compound had even greater potency
and excellent pharmacokinetics –NITD609 (Yeung
et al. 2010; see also Smith et al. in this Special Issue of
Parasitology – volume 140, 2013) see Fig. 5.
GNF156
A second molecule from the Novartis consortium,
led this time from the Genomics Institute of the
Novartis Research Foundation (GNF) in San Diego,
delivered GNF156 as a new clinical compound, again
in collaboration with MMV. The compound, an
imidazolopiperazine, has high potency against blood
and liver stages in vitro and in vivo, and has been
shown to kill gametocytes demonstrating potential in
transmission blocking. The series acts via a novel
mechanism, involving a previously unannotated gene
now called P. falciparum Cyclic Amine Resistance
Locus (Pfcarl) (Meister et al. 2011). The compound
is well tolerated in preclinical safety studies, and has
now safely completed phase I studies.
The imidazolopiperazine series, exempliﬁed by 3,
was also identiﬁed from whole cell screening. The
ﬁrst task was to replace metabolically labile aromatic
substituents and to stabilize likely positions of
metabolism with blocking halogens. This led to
compound 4 whereby potency and stability had
both been improved – though not suﬃciently for
a candidate. Metabolite identiﬁcation and excellent
medicinal chemistry then led to the isomer,
GNF156, whereby the metabolically susceptible
position on the piperazine was blocked with two
methyl groups. GNF156 demonstrated a good over-
all proﬁle with an ED99 in the P. berghei mouse of
1·1 mg/kg (Nagle et al. 2012) as shown in Fig. 6.
DSM265
The P. falciparum enzyme dihydroorotate dehydro-
genase (PfDHODH) is known to be essential for the
survival of the parasite. A team led byMeg Phillips at
the University of Texas Southwestern, in collabor-
ation with the University of Washington, Monash
University and MMV identiﬁed a potent and
Fig. 6. GNF156: Hit to Candidate.
Fig. 5. NITD609: Hit to Candidate.
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selective triazolopyrimidine-based inhibitor DSM1
via a high-throughput enzyme screen. The three-
dimensional structure of the enzyme-inhibitor
complex was resolved and the subsequent lead
optimization programme led to the identiﬁcation of
the preclinical candidate. DSM1 was an interesting
molecule but with non-optimal pharmacokinetics on
repeat dosing and insuﬃcient potency. First of all,
progress was made to improve pharmacokinetics by
substituting electron-withdrawing groups in the
aniline ring; due to the hydrophobic nature of the
binding site only lipophilic groups have had major
success here, e.g. DSM191 (Gujjar et al. 2009).
A second breakthrough came using the X-ray crystal
structure; it was clear that limited substitution oﬀ the
triazolo carbon could be achieved and, combined
with electron withdrawal could reduce desolvation
of the heterocycle and improve potency. These
changes, Fig. 7, in collaboration withGSK, delivered
DSM265, which has a good potency and safety
proﬁle from preclinical studies (Coteron et al. 2011).
If successful, it will be the ﬁrst antimalarial che-
motherapy to target DHODH. The compound is
currently in preclinical development, with the
expectation to enter Phase I trials in early 2013.
P218
Dihydrofolate reductase (DHFR) inhibitors such
as pyrimethamine have been widely used for the
treatment of malaria, although their clinical eﬃcacy
has been compromised by resistance. P218 is a next
generation inhibitor of DHFR that has been deliv-
ered by the Thai BIOTEC group in collaboration
with Monash University, the London School of
Hygiene and Tropical Medicine and MMV; it has
largely ﬁnished preclinical development. Impress-
ively, the team designed P218 using structure-based
design methods to have a high aﬃnity to both the
parent and mutated enzymes and to also kill both
wild type and clinically-relevant resistant strains.
The challenge of sustaining activity across even
quadruple-mutated enzymes was overcome by start-
ing with the pyrimethamine scaﬀold and then using
a ﬂexible side-chain that could adopt a variety
of conformations to achieve potency such as P65.
A carboxylic acid was also found to be optimal in
selective binding to a key protein arginine in the
parasite, but not in man (see Fig. 8). P218 has a good
pharmacokinetic proﬁle, is selective and highly
eﬃcacious; the initial safety testing with P218
indicated a good safety margin between the toxicity
in animals and the predicted eﬀective human dose
(Yuthavong et al. 2012).
KEY CRITERIA FOR NEW TREATMENTS
FOR MALARIA
In the development of new treatments for malaria a
number of key generic criteria need to be met by any
drug candidates, in addition to those eradication
criteria already discussed: high potency, low cost,
high stability in tropical conditions, good develop-
ment potential (e.g. acceptable solubility), a low
chance for resistance developing, and high levels of
safety in the target populations.
The development of resistance is a constant
challenge in the treatment of malaria as with any
infectious disease. In the development of new
medicines it is important that molecules are selected
Fig. 7. DSM265: Hit to Candidate.
Fig. 8. P218: Pyrimethamine to Candidate.
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that have a low potential for resistance development.
This means screening against existing targets and
resistance mechanisms and selecting molecules that,
ideally, hit more than one target to increase resilience
to the development of resistance. The frequency of
resistance development and the ﬁtness cost to the
parasite of resistance are other factors that should be
taken into account. Resistant phenotypes that have a
high ﬁtness cost would require extreme selective
pressure to spread. A standardized in vitro method
to assess these characteristics quantitatively in
P. falciparum during the early phases of the drug
development process has recently been developed
(Ding et al. 2012). Notably, assessing the risk of resis-
tance induction has helped project teams to down-
prioritize series, allowing them to focus their eﬀorts
on more promising candidates (Sanz et al. 2011).
Finally, a high level of safety is of paramount
importance. The populations most vulnerable to
malaria at this time are pregnant women and children
under 5 years of age. Chemoprevention is already a
key malaria control strategy in these populations and
as malaria prevalence decreases according to an
elimination scenario, the wider population at large
also become vulnerable due to decreased immunity.
Consequently, many of the individuals that will
receive the new chemoprotective agents will not have
clinical malaria. This raises the bar in terms of the
levels of safety required for any new medication.
Discovery of molecules to clear blood-stage parasites:
TCP1 – rapid clearance; TCP2 – long duration
The rapid increase in the availability of genome data
and high-throughput screening technology over the
past decade initially raised hopes for the identiﬁcation
and development of many new classes of drugs for
malaria (Burrows and Waterson, 2011). For some
time it was thought that understanding the malaria
parasite at the molecular level would accelerate
the discovery of new antimalarials by identifying
compounds that could inhibit key enzymes or cell
receptors in the parasite. Unfortunately, these
molecular-based approaches have not proved eﬃcient
in identifying validated targets (Payne et al. 2007).
For parasitic diseases such as malaria, screening
can also be carried out against the whole cell, and
this has proved an extremely valuable approach.
A considerable advantage of parasite-based screening
is that it can identify compounds that act on more
than one molecular target. Drugs that attack more
than one cellular pathway should be less vulnerable to
the development of resistance (Ding et al. 2012).
The industrial partners of the malaria research
community have been quick to adopt this alternative
approach and by leveraging their ability to generate
automated systems, pharmaceutical companies and
institutes such as Eskitis under the leadership of
Avery and colleagues have screened over six million
compounds against the erythrocytic stages of the
malaria parasite (Duﬀy and Avery, 2012; Guiguemde
et al. 2012). This has led to the identiﬁcation of over
25000 compounds that show some eﬀect on the
parasite at sub-micromolar concentrations. Data on
many of these compounds has been released to the
malaria community online to encourage drug-lead
identiﬁcation eﬀorts. These data can be located at:
https://www.ebi.ac.uk/chembl/malaria/. GlaxoSmith-
Kline (Gamo et al. 2010), Novartis (Plouﬀe et al.
2008) and St. Jude Children’s Research Hospital
(Guiguemde et al. 2010) have released chemical
structures and associated information on approxi-
mately 19000 compounds with conﬁrmed blood-
stage activity against P. falciparum that were
identiﬁed from a combined screening eﬀort of over
4 million compounds from the companies’ and
University’s chemical libraries. In December 2011,
MMV announced that it was making a library of
400 compounds with conﬁrmed activity against the
blood-stage of P. falciparum available to the research
community free of charge. Each of the compounds
was selected, pragmatically on availability and other
criteria, from the published data sets listed above
(Spangenberg et al. 2013).
The widespread adoption of whole-parasite
screening has led to the generation of a new assay
‘the parasite reduction ratio’ that allows the direct
determination of in vitro killing rates for potential
antimalarials (Sanz et al. 2012). A number of in vitro
techniques have been developed to investigate the
eﬀect of drug treatment on asexual parasite survival
and growth, and are used for both drug development
and resistance-monitoring studies. Although these
assays use a variety of approaches, they all rely on
measuring metabolic activity as a proxy for parasite
viability. However, relying on proxies can lead to
incorrect interpretations. For example, viable but
metabolically inactive parasites could be measured as
dead, while parasites committed to death could still
display metabolic activity. The new assay is based on
limiting serial dilution of treated parasites and re-
growth monitoring which allows the direct in vitro
measurement of the eﬀect of antimalarial compounds
on parasite viability. In addition, drug lag phase, that
is the time required for a drug to achieve its maximal
killing, can be precisely identiﬁed and timed. The
parasite reduction ratio clearly shows the diﬀerent
speeds of action of atovaquone, pyrimethamine,
chloroquine and artemisinin (Fig. 9). This is par-
ticularly relevant with respect to ﬁnding molecules
that are deliberately fast (TCP1) or slow onset
(TCP4) blood-stage killers.
The parasite clearance rates of potential anti-
malarials can also be measured in two in vivo systems,
which are complementary to the parasite reduction
ratio. The ﬁrst system examines the impact of
the candidate molecule on P. berghei in mice.
However, the use of a rodent plasmodial species
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as a surrogate for P. falciparum is a drawback of
this model. The second system uses a falciparum
murine model of malaria by generating strains of
P. falciparum that can infect immunodeﬁcient mice
engrafted with human erythrocytes – the humanized
SCIDmouse (Angulo-Barturen et al. 2008; Jimenez-
Diaz et al. 2009).
Despite the focus of screening currently on whole-
cell systems, it does not mean that target-based drug
discovery is redundant. The lack of target-based drug
discovery projects is more a result of the lack of high
quality targets than the approach itself. Indeed, if
whole cell screening hits are discovered with attrac-
tive phenotypes, then target-ﬁnding techniques can
be highly relevant as a strategy to identify a back-up
series from a target-based screen.
Finally, ﬁnding compounds with long durations of
exposure in patient blood suﬃcient to maintain
eﬃcacy for periods of time beyond just curing the
patient , hence also protecting against new infections
(TCP2), is also a priority. Pharmacokinetics clearly
becomes the deﬁning parameter in this case and once
in vitro metabolism has been signiﬁcantly reduced,
there is likely to be need for substantial preclinical
in vivo pharmacokinetic work. Following this sub-
sequent modelling to humans, demonstration of
predicted clinical relevance is needed, as well as
extensive safety testing to ensure an acceptable
cardiovascular risk in addition to demonstrating
that a prolonged exposure is well tolerated. In
addition, early in vivo screening of whole cell actives
can be an eﬃcient method to identify starting points
rapidly for further optimization.
Developing new drugs for the treatment of P. vivax:
TCP3a – relapse prevention
The lack of safe and easily administered drugs for
radical cure of P. vivax is a critical gap in the malaria
eradication agenda. To achieve eradication, the
entire human reservoir of malaria parasites must be
eliminated, including latent dormant stages. This
will be particularly diﬃcult to achieve for P. vivax
because of the relapsing liver-stage hypnozoites that
are refractory to treatment with all current anti-
malarials except primaquine.
One of the key challenges in developing new drugs
forP. vivax is the inability to conduct cellular screens
for anti-relapse agents. To develop a P. vivax liver-
stage assay, the malaria community needs to secure a
supply of viable sporozoites. Maintaining P. vivax in
continuous in vitro culture to provide a clonal supply
of parasites on which the mosquitoes can feed is the
major barrier to this. Stable and infective hepatocyte
lines are also needed, as primary human liver cells are
often of variable quality and lose their diﬀerentiation
in culture (Wells et al. 2010).
A standard cascade for the discovery and develop-
ment of drugs for anti-relapse with P. vivax would
start with a simple cell assay, followed by conﬁr-
mation of the activity in vivo in an animal model,
and then proceed via clinical proof of concept in an
‘Out of Transmission’ model to full human clinical
trials. With no cell assay for P. vivax, the historical
foundation of anti-relapse drug discovery has been
use of an in vivo system: the infection of rhesus
monkeys with P. cynomolgi. This simian parasite
relapses in a regular time frame (around 22 days) and
thus new compounds can be dosed once the patent
blood stages have been cleared and the animal
parasitaemia monitored for a relapse. It was this
model that was originally used in the screening that
led to the discovery of the drug primaquine and the
follow-on compound, tafenoquine. However, for the
development of a large drug discovery programme
an in vitro model is required to facilitate high-
throughput screening of compounds. Cultured
hepatic stages of P. cynomolgi have been established
in rhesus hepatocytes but determination of which
non-dividing forms correspond to hypnozoites has
proven diﬃcult. It has been suggested that, by noting
the response of these non-dividing forms to an anti-
relapse drug and an antimalarial that is not active
against hypnozoites, a better characterization of true
hypnozoites can be obtained (Dembele et al. 2011).
It is this in vitro assay that is currently the pragmatic
primary assay for anti-relapse data to drive medicinal
chemistry.
Thus a key priority is to deliver a liver-stage assay
of P. vivax to drive future medicinal chemistry in the
pursuit of new anti-relapse medicines.
Focusing on transmission blocking:
TCP3b – gametocytocidal agents
As mentioned above, primaquine is eﬀective in
blocking transmission to the mosquito from a single
human dose of 0·75mg/kg. WHO has also recom-
mended use of a lower dose (0·25 mg/kg) under
certain circumstances and this is therefore the gold
standard to beat. The challengewill persist whilst this
recommendation remains (and that will depend
on the results of future studies), until extensive
Fig. 9. The Parasite Reduction Ratio for four standard
antimalarials: artemisinin, chloroquine, pyrimethamine
and atovaquone. Reproduced from ©Sanz LM et al.
PlosONE 7(2) e30949. doi:10.1371/journal.pone.0030949
136Jeremy N Burrows and others
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182013000826
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 09:56:23, subject to the Cambridge Core terms of use, available at
resistance to primaquine is demonstrated or, ﬁnally,
hitherto unknown adverse events from the low dose
become apparent. However, the unsuitability for
pregnant women and very young children highlights
improvements necessary in next generationmolecules.
The strategy is to target host gametocytes such that
mature gametocytes are either killed or rendered
inactive. In such a scenario, following amosquito bite
parasite gamete formation is blocked either because
of an absence of mature gametocytes in the blood, or
their inactivation. With gamete formation inhibited
in the mosquito then there cannot be further
development of vector-stage parasites and hence the
life-cycle is blocked. This approach reduces the
transmission window for a patient and the length of
this time-window is deﬁned by the rate with which
gametocytes are killed or inactivated. For primaquine
this transmission window appears to be around
24–48 h (Rieckmann et al. 1968).
A second type of activity of a compound can be
direct on the mosquito stages of the parasite. Such
activity is desirable, in that it will result in trans-
mission being blocked even during the transmission
window. The risk is that in the absence of a
gametocytocidal agent such a transmission window
can be very long and hence, unless a drug has a
phenomenally long half-life, for as long as mature
gametocytes circulate, its eﬀectiveness is likely to be
limited (Bousema et al. 2010).
Pragmatically, the current priority is to develop
molecules that combine host gametocytocidal activity
of an equal potency to that displayed against asexual
blood stages. The optimum cascade for identifying
compounds aﬀecting transmission involves an assay
that conﬁrms inhibition of mature gametocytes
followed by a standard falciparummembrane feeding
assay (SMFA). Potential additional in vivo work
including a mouse-to-mouse transmission may also
be instructive particularly in order to compare against
primaquine, which requires metabolism for eﬃcacy
(Sinden et al. 2012a,b).
Chemoprotection for malaria elimination:
TCP4 – prophylactics
In a malaria-elimination scenario, individuals will be
at risk of reinfection from areas that retain a human
reservoir of parasites. In this context, drugs will be
needed for chemoprotection of individuals in once
endemic areas. To prevent chemoprotection strat-
egies from jeopardizing drugs used for the treatment
of clinical disease through the development of
resistance, it is important that the two types of
antimalarial are well diﬀerentiated. One possible
mechanism for facilitating this could be to examine
the potential of slow-onset blood stage-acting mol-
ecules (such as those with a delayed death phenotype)
or those that only kill liver schizonts for chemo-
protection strategies.
Longer duration blood-stage assays (96 h) can be
run and compared with results from earlier time
points (48 h or 72 h) to prioritize compounds with
slow blood-stage action (Dahl and Rosenthal, 2007).
To identify series that kill the developing liver stages,
high-throughput screening can be performed against
rodent liver-stage parasites in human liver cell lines
(e.g. HepG2) (Meister et al. 2011). Falciparum and
vivax liver-stage assays are still embryonic but,
ideally, it would always be important to conﬁrm
activity on the human parasite prior to signiﬁcant
investment in a drug discovery programme.
In vivo rodent models are available such as
the P. berghei sporozoite infection model and these
can even be performed using imaging to detect
parasitaemia prior to a blood stage infection (e.g.
Sanchez et al. 2004).
SUMMARY
Currently, the mainstay treatments for malaria are
eﬀective and safe. Furthermore, new clinical entities
that oﬀer signiﬁcant advances over existing regimens
continue to progress well and a range of compound
and project options is available in Preclinical
Development and earlier. However, the tenacity of
the parasite in thwarting our attempts to kill it is
unparalleled. If we are serious about controlling and
ultimately eradicating the parasite then together
we need sustained eﬀorts to discover, develop and
deliver newmedicines that not only cure patients, but
block transmission, block relapse and oﬀer protection
against new infections. The advent of the newMMV
TPPs and TCPs will help to guide researchers
towards these ends.
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